title: On the mechanism of interaction of potent surmountable and insurmountable antagonists with the prostaglandin D2 receptor CRTH2.
abstract: Chemoattractant receptor-homologous molecule expressed on T helper 2 cells (CRTH2) has attracted interest as a potential therapeutic target in inflammatory diseases. Ramatroban, a thromboxane A2 receptor antagonist with clinical efficacy in allergic rhinitis, was recently found to also display potent CRTH2 antagonistic activity. Here, we present the pharmacological profile of three ramatroban analogs that differ chemically from ramatroban by either a single additional methyl group (TM30642), or an acetic acid instead of a propionic acid side chain (TM30643), or both modifications (TM30089). All three compounds bound to human CRTH2 stably expressed in human embryonic kidney 293 cells with nanomolar affinity. [3H]Prostaglandin D2 (PGD2) saturation analysis reveals that ramatroban and TM30642 decrease PGD2 affinity, whereas TM30643 and TM30089 exclusively depress ligand binding capacity (Bmax). Each of the three compounds acted as potent CRTH2 antagonists, yet the nature of their antagonism differed markedly. In functional assays measuring inhibition of PGD2-mediated 1) guanosine 5'-O-(3-thio)triphosphate binding, 2) beta-arrestin translocation, and 3) shape change of human eosinophils endogenously expressing CRTH2, ramatroban, and TM30642 produced surmountable antagonism and parallel rightward shifts of the PGD2 concentration-response curves. For TM30643 and TM30089, this shift was accompanied by a progressive reduction of maximal response. Binding analyses indicated that the functional insurmountability of TM30643 and TM30089 was probably related to long-lasting CRTH2 inhibition mediated via the orthosteric site of the receptor. A mechanistic understanding of insurmountability of CRTH2 antagonists could be fundamental for development of this novel class of anti-inflammatory drugs.
authors.affiliation: 7TM Pharma A/S, Fremtidsvej 3, 2970 Hørsholm, Denmark.
authors.forename: Jesper Mosolff
authors.initials: JM
authors.lastname: Mathiesen
authors.forename: Arthur
authors.initials: A
authors.lastname: Christopoulos
authors.forename: Trond
authors.initials: T
authors.lastname: Ulven
authors.forename: Julia F
authors.initials: JF
authors.lastname: Royer
authors.forename: Mercedes
authors.initials: M
authors.lastname: Campillo
authors.forename: Akos
authors.initials: A
authors.lastname: Heinemann
authors.forename: Leonardo
authors.initials: L
authors.lastname: Pardo
authors.forename: Evi
authors.initials: E
authors.lastname: Kostenis
mesh_terms: D000818:Animals; D019556:COS Cells; D002460:Cell Line; D002522:Chlorocebus aethiops; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007700:Kinetics; D011448:Prostaglandin Antagonists / Q000494:pharmacology*; D011869:Radioligand Assay; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors*; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors*; D014316:Tritium
chemical_list: D011448:Prostaglandin Antagonists; D011971:Receptors, Immunologic; D011982:Receptors, Prostaglandin; D014316:Tritium; C036293:prostaglandin D2 receptor